Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETHEMA LAL-RI/96: Treatment for Standard Risk Acute Lymphoblastic Leukemia
NCT00494897Phase 4Completed
- Sponsor
- Fundación PETHEMA
- Start
- Jun 1996
- Primary completion
- May 2007
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of asparaginase escherichia coli, cyclophosphamide, cytarabine, daunorubicin, mercaptopurine in acute lymphoblastic leukemia (ALL), sponsored by Fundación PETHEMA. Started Jun 1996; status: completed.
02
Drugs
asparaginase escherichia colicyclophosphamidecytarabinedaunorubicinmercaptopurine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00494897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00494897.